Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Neurovive Pharmaceutical: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: NeuroVive Pharmaceutical AB (publ)(STO:NVP), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company’s product CicloMulsion®. The study, known as CiPRICS, is being conducted by Skåne University Hospital and will evaluate the product’s ability to prevent acute […]

Read More »

BioGaia: Positive Results in First Chinese Study with BioGaia’s Drops in Infants with Colic

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: A Chinese study of infants with colic shows that babies given Lactobacillus reuteri Protectis cry significantly less compared to babies given placebo. The newly published study is the fifth positive colic study with Lactobacillus reuteri Protectis and the results confirm the positive results of earlier studies. 100 per cent treatment successTreatment success […]

Read More »

More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes

More information about the highly anticipated new cholesterol lowering drugs from Amgen and Sanofi/Regeneron emerged today. A new new analysis of available data from early trials with PCSK9 inhibitors adds to the growing evidence showing that the drugs– Amgen’s evolocumab and Sanofi’s alirocumab– dramatically lower LDL cholesterol and offers additional preliminary evidence showing that they are safe and may confer a […]

Read More »

Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth

WICHITA, Kan., April 27, 2015 /PRNewswire-USNewswire/ — For about a century, a known common property of cancer cells is their ability to utilize and catabolize glucose at a high rate. This metabolic alteration of cancer cells is called the ”Warburg phenomenon”, that is an increased flow through glycolysis in spite of high oxygen presence, leading to […]

Read More »

Microneedle Patch for Measles Vaccination Could Be a Game Changer

ATLANTA, April 27, 2015 /PRNewswire-USNewswire/ — A new microneedle patch being developed by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) could make it easier to vaccinate people against measles and other vaccine-preventable diseases.  The microneedle patch is designed to be administered by minimally trained workers and to simplify […]

Read More »

Merck’s diabetes drug Januvia succeeds in heart safety trial

(Reuters) – Merck and Co’s diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product. Merck shares rose nearly 4 percent in after-hours trading following the announcement on Januvia, which had sales […]

Read More »

Celladon says heart treatment fails in trial

(Reuters) – Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial. “We are surprised and very disappointed that Mydicar failed to meet the endpoints in the CUPID2 trial, and we are rigorously analyzing the data in an attempt to better understand the observed […]

Read More »

New Prenatal DNA Test For Down Syndrome Dramatically Reduces Errors

The results of a new study offer very good news for expectant parents: a remarkably accurate prenatal genetic test for Down syndrome that requires only a blood sample from the mother. Expectant parents have a lot to deal with. What can a mom-to-be eat, drink, or do to ensure the health of the baby? There […]

Read More »

Bristol-Myers says hepatitis C drug combination succeeds in study

<span class="articleLocation”>(Reuters) – Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc’s Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study. Data presented at the International Liver Congress on Saturday showed that the combination cured 94 percent of the patients […]

Read More »

Late-Breaking Oral Presentation at The International Liver Congress (ILC 2015) Highlights RG-101’s Potent, Durable and Pan-Genotypic Effects in Diverse HCV Population

LA JOLLA, Calif., April 25, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today presented new data strengthening the profile of RG-101, a wholly-owned, GalNAc-conjugated anti-miR targeting microRNA-122 (“miR-122”) for the treatment of HCV, during an oral late-breaking session at ILC 2015 in Vienna, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom